Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6XAA

SARS CoV-2 PLpro in complex with ubiquitin propargylamide

Summary for 6XAA
Entry DOI10.2210/pdb6xaa/pdb
DescriptorNon-structural protein 3, Ubiquitin-propargylamide, ZINC ION, ... (4 entities in total)
Functional Keywordssars cov-2, papain-like protease, ubiquitin activity based probe, covid19, hydrolase-substrate complex, hydrolase/substrate
Biological sourceSevere acute respiratory syndrome coronavirus 2 (2019-nCoV)
More
Total number of polymer chains2
Total formula weight44611.12
Authors
Klemm, T.,Calleja, D.J.,Richardson, L.W.,Lechtenberg, B.C.,Komander, D. (deposition date: 2020-06-04, release date: 2020-06-17, Last modification date: 2024-10-23)
Primary citationKlemm, T.,Ebert, G.,Calleja, D.J.,Allison, C.C.,Richardson, L.W.,Bernardini, J.P.,Lu, B.G.,Kuchel, N.W.,Grohmann, C.,Shibata, Y.,Gan, Z.Y.,Cooney, J.P.,Doerflinger, M.,Au, A.E.,Blackmore, T.R.,van der Heden van Noort, G.J.,Geurink, P.P.,Ovaa, H.,Newman, J.,Riboldi-Tunnicliffe, A.,Czabotar, P.E.,Mitchell, J.P.,Feltham, R.,Lechtenberg, B.C.,Lowes, K.N.,Dewson, G.,Pellegrini, M.,Lessene, G.,Komander, D.
Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2.
Embo J., 39:e106275-e106275, 2020
Cited by
PubMed Abstract: The SARS-CoV-2 coronavirus encodes an essential papain-like protease domain as part of its non-structural protein (nsp)-3, namely SARS2 PLpro, that cleaves the viral polyprotein, but also removes ubiquitin-like ISG15 protein modifications as well as, with lower activity, Lys48-linked polyubiquitin. Structures of PLpro bound to ubiquitin and ISG15 reveal that the S1 ubiquitin-binding site is responsible for high ISG15 activity, while the S2 binding site provides Lys48 chain specificity and cleavage efficiency. To identify PLpro inhibitors in a repurposing approach, screening of 3,727 unique approved drugs and clinical compounds against SARS2 PLpro identified no compounds that inhibited PLpro consistently or that could be validated in counterscreens. More promisingly, non-covalent small molecule SARS PLpro inhibitors also target SARS2 PLpro, prevent self-processing of nsp3 in cells and display high potency and excellent antiviral activity in a SARS-CoV-2 infection model.
PubMed: 32845033
DOI: 10.15252/embj.2020106275
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.7 Å)
Structure validation

236620

PDB entries from 2025-05-28

PDB statisticsPDBj update infoContact PDBjnumon